Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 5 - Biology of BRCA1 and BRCA2 genes and implications for cancer management

  • from SECTION 2 - THE TRANSLATION OF BIOLOGY TO THE CLINIC
  • Edited by Sean Kehoe, Richard J. Edmondson, Martin Gore, Iain A. McNeish
  • Book:
    Gynaecological Cancers
    Published online:
    05 February 2014
    Print publication:
    01 June 2011, pp 57-74

  • Summary

    The importance of BRCA1 and BRCA2 genes stems from the fact that they are 'caretaker' cancer-susceptibility genes, which encode molecules that act as sensors of DNA defects and participate in the repair process. The main function of BRCA2 is its role in HR-mediated DNA DSB repair through its direct interaction with RAD51. Most ovarian cancers occur sporadically, although approximately 10% of patients report an associated family history of the disease. In unselected series, about 6-15% of ovarian cancers have been found to be due to BRCA mutations. The ability to predict an individual's cancer risk accurately is limited by the influence of factors other than whether a BRCA1 or BRCA2 mutation has been inherited. The demonstration of single-agent anti-tumour activity and the wide therapeutic index of PARP inhibitors in BRCA1 and BRCA2 mutation carriers with advanced ovarian and breast cancers provide strong evidence for the clinical application of this approach.